UNSPSC 51171973: Alglucosidase alfa

This classification denotes an enzyme replacement preparation with the molecular formula C4758H7262N1274O1369S35, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DTI67O9503, more generally known as alglucosidase alfa. European Medicines Agency schedules alglucosidase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21275. The term ALGLUCOSIDASE ALFA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.

Most nations schedule Alglucosidase alfa under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, ALGLUCOSIDASE ALFA remains the US FDA Preferred Term for this commodity.. Alglucosidase alfa bears US NLM identifiers UMLS ID C1703294 and NCI Concept Code C65221.

UNSPSC 51171973 Alglucosidase alfa is a Commodity code that names a specific enzyme replacement therapy used to treat Pompe disease, but the recent state and local solicitations posted under this code show little alignment with the pharmaceutical product itself. The three recent opportunities—a Collin County offender drug testing RFP, a Texas HHS Commission RFI on direct-to-manufacturer prescriptions, and a Minnesota cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—span specimen collection and testing services, pharmacy benefit program design, and bulk pharmaceutical sourcing, none of which map directly to procurement of alglucosidase alfa as a named therapeutic agent. The code appears to be misapplied across these opportunities, suggesting either broad tagging of pharmaceutical-adjacent work or classification inconsistency in the source jurisdictions' procurement systems.

Recent activity concentrates in Texas and Minnesota, with the Collin County Community Supervision and Corrections Department posting an RFP (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026; the Texas HHS Commission issuing an exploratory RFI (closed April 3, 2026) on direct-to-manufacturer prescription programs; and the Minnesota Department of Administration's MMCAP cooperative purchasing alliance issuing an RFP (due March 26, 2026) for generic pharmaceuticals and OTC products across multiple participating state and local jurisdictions. None of these opportunities explicitly request alglucosidase alfa procurement, and the code does not appear to reflect active state or local buying activity in the therapeutic enzyme replacement category as of mid-2026.